Investor Relations

Stock Information

Symbol

Nasdaq: VTGN

Price

Change

Volume

52 week Low/High

Day Low/High

Company Overview

VistaGen Therapeutics, Inc. (NASDAQ: VTGN) is a clinical-stage biopharmaceutical company committed to developing differentiated new generation medications for central nervous system (CNS) diseases and disorders with high unmet need. Our product candidate portfolio includes three differentiated clinical-stage candidates, PH94B, PH10 and AV-101, which we are developing for multiple CNS indications. Each of VistaGen’s drug candidates has a fundamentally different mechanism of action from all currently approved oral drug treatments, and potential for rapid onset therapeutic effects, convenient at-home self-administration, and an exceptional safety profile. We aim to become a fully-integrated biopharmaceutical company that develops and commercializes innovative CNS therapies for large and growing mental health and neurology markets where current treatments are inadequate to meet the needs of millions of patients and caregivers worldwide.

Contact Information

VistaGen Therapeutics, Inc.
Mark A. McPartland
Vice President, Corporate Development
(650) 577-3606
markmcp@vistagen.com

Investor Relations
KCSA Strategic Communications
Valter Pinto / Allison Soss
(212) 896-1254 / (212) 896-1267
VistaGen@KCSA.com

Public Relations
KCSA Strategic Communications
Caitlin Kasunich / Lisa Lipson
(212) 896-1241 / (508) 843-6428
VistaGen@KCSA.com

Transfer Agent
Computershare, Inc.
P.O. BOX 30170
College Station, TX 77842
(800) 368-5948
www-us.computershare.com